DAPTA, a C-C Chemokine Receptor 5 (CCR5), Leads to the Downregulation of Notch/NF-κB Signaling and Proinflammatory Mediators in CD40+ Cells in Experimental Autoimmune Encephalomyelitis Model in SJL/J Mice

Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system characterized by motor deficits, cognitive impairment, fatigue, pain, and sensory and visual dysfunction. CD40, highly expressed in B cells, plays a significant role in MS pathogenesis. The experimental autoimmune encephalomyelitis (EAE) mouse model of MS has been well established, as well as its relevance in MS patients. This study aimed to evaluate the therapeutic potential of DAPTA, a selective C-C chemokine receptor 5 (CCR5) antagonist in the murine model of MS, and to expand the knowledge of its mechanism of action. Following the induction of EAE, DAPTA was administrated (0.01 mg/kg, i.p.) daily from day 14 to day 42. We investigated the effects of DAPTA on NF-?B p65, I?Ba, Notch-1, Notch-3, GM-CSF, MCP-1, iNOS, and TNF-a in CD40(+) spleen B cells using flow cytometry. Furthermore, we also analyzed the effect of DAPTA on NF-?B p65, I?Ba, Notch-1, Notch-3, GM-CSF, MCP-1, iNOS, and TNF-a mRNA expression levels using qRT-PCR in brain tissue. EAE mice treated with DAPTA showed substantial reductions in NF-?B p65, Notch-1, Notch-3, GM-CSF, MCP-1, iNOS, and TNF-a but an increase in the I?Ba of CD40(+) B lymphocytes. Moreover, EAE mice treated with DAPTA displayed decreased NF-?B p65, Notch-1, Notch-3, GM-CSF, MCP-1, iNOS, and TNF-a and but showed increased I?Ba mRNA expression levels. This study showed that DAPTA has significant neuroprotective potential in EAE via the downregulation of inflammatory mediators and NF-?B/Notch signaling. Collectively, DAPTA might have potential therapeutic targets for use in MS treatment.